Interventional News’ top 10 most popular stories of November 2021 

355

Interventional NewsNovember’s top 10 features a pilot study regarding cryoablation for the treatment of early-stage, low-risk breast tumours, as well as data indicating that the Ellipsys vascular access system (Avenu Medical/Medtronic) offers an “excellent alternative” to arteriovenous fistula creation via surgical procedures in end-stage renal disease patients. In addition, the declaration of UK interventional radiologists of why to attend British Society of Interventional Radiology (BSIR) (8—10 December, Glasgow, United Kingdom) also attracted many readers.  

1)Cryoablation could freeze out lumpectomy in early-stage, low-risk breast tumours 

A pilot study, published in the Journal of Cancer Therapy, reveals that percutaneous cryoablation of early-stage, low-risk breast cancer tumours smaller than 15mm presents a potential substitute for lumpectomy.  

2)Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data 

The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (AVFs) for haemodialysis—with new, long-term data suggesting it offers an “excellent alternative” to AVF creation via surgical procedures in end-stage renal disease patients. That is according to Jeffrey Hull, an interventional radiologist and director of the Richmond Vascular Institute in Richmond, USA, who presented five-year results from the Ellipsys US pivotal trial at this year’s American Society of Nephrology (ASN) Kidney Week (2–7 November 2021, virtual). 

3)UK interventional radiologists declare top reasons to attend BSIR 2021 in Glasgow 

Hear from Alex Barnacle (London; British Society for Interventional Radiology [BSIR] communications chair), Peter Littler (Newcastle; the 2021 Scientific Programme Committee chair), Ian McCafferty (Birmingham; current BSIR president) and Phil Haslam (Newcastle; incoming BSIR president) about what they are most looking forward to at this year’s meeting. 

4)TCT 2021: Six-month RADIANCE-HTN TRIO results “open a window” for renal denervation 

Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasound renal denervation to a sham procedure for treatment-resistant hypertension, demonstrate the additional effects of pharmacologic intervention with maintenance of a blood pressure-lowering effect of renal denervation at six months, according to investigators. 

5)TCT 2021: Randomised trials show “consistent” reduction in blood pressure through renal denervation 

Randomised placebo-controlled trials show consistently that renal denervation provides significant reduction in ambulatory and office blood pressure, the findings of a systematic review and meta-analysis suggest. 

6)Sarasota team completes “world first” procedure with ACE Xtend robotic system 

XACT Robotics recently announced what it describes as the world’s first remote-controlled robotic instrument insertion and non-linear steering during an interventional oncology percutaneous procedure with ACE Xtend. 

7)Innovative embolic device shows promise for interventional oncology drug delivery 

Fluidx Medical’s GPX embolic device has released initial results for Oncology Drug Delivery. Fluidx Medical Technology announced that a next-generation, doxorubicin-loaded GPX embolic device was featured at the recent symposium on clinical interventional oncology (CIO) conference highlighting the technology’s potential for oncology drug delivery.  

8)SIO announces ACCLAIM clinical trial with support from industry partners 

The Society of Interventional Oncology (SIO) has announced the launch of the society’s first clinical trial—Ablation with confirmation of colorectal liver metastases (ACCLAIM) prospective trial for microwave ablation as a local cure. An SIO press release details that this multi-million-dollar trial is funded collectively through grants from Boston Scientific Corporation, NeuWave Medical (part of Ethicon), and Varian, a Siemens Healthineers company. 

9)Philips announces large-scale study outcomes on use of IVUS in peripheral interventions 

Royal Philips announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health outcomes of peripheral vascular interventions guided by intravascular ultrasound (IVUS). 

10) Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study  

Medtronic today announced findings from a new study of patient preferences for the treatment of hypertension. The findings are set to be presented during the “What’s Novel in Interventional Hypertension” session at the 33rd Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando, USA and virtual)—the yearly scientific symposium of the Cardiovascular Research Foundation. 

 


LEAVE A REPLY

Please enter your comment!
Please enter your name here